Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.22.1
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Mar. 31, 2022
Mar. 31, 2021
Condensed Consolidated Statements of Operations and Comprehensive Loss        
Revenues $ 1,943 $ 765 $ 2,322 $ 1,880
Cost of goods sold 48 493 201 1,275
Gross profit 1,895 272 2,121 605
Operating expenses:        
Research and development 5,551 2,162 11,393 6,892
General and administrative (related party of $0, $491, $250 and $1,394) 8,526 5,313 23,522 15,385
Total operating expenses 14,077 7,475 34,915 22,277
Operating loss (12,182) (7,203) (32,794) (21,672)
Other income (expense):        
Interest expense (related party of $0, $610, $810 and $1,836) (250) (612) (1,187) (1,841)
Interest income 40 152 111 183
Royalty income 2 1 7 3
Forgiveness of note payable and accrued interest - SBA loan 0 0 607 0
Other 0 0 6 0
Total other (expense) (208) (459) (456) (1,655)
Consolidated net loss (12,390) (7,662) (33,250) (23,327)
Net loss attributable to noncontrolling interest 0 1 1 4
Net loss attributable to iBio, Inc. (12,390) (7,661) (33,249) (23,323)
Preferred stock dividends 0 (64) (88) (195)
Net loss attributable to iBio, Inc. stockholders (12,390) (7,725) (33,337) (23,518)
Comprehensive loss:        
Consolidated net loss (12,390) (7,662) (33,250) (23,327)
Other comprehensive loss - unrealized loss on debt securities (103) (16) (131) (36)
Comprehensive loss $ (12,493) $ (7,678) $ (33,381) $ (23,363)
Loss per common share attributable to iBio, Inc. stockholders - basic $ (0.06) $ (0.04) $ (0.15) $ (0.12)
Loss per common share attributable to iBio, Inc. stockholders - diluted $ (0.06) $ (0.04) $ (0.15) $ (0.12)
Weighted-average common shares outstanding - basic 218,096 215,539 217,986 188,493
Weighted-average common shares outstanding - diluted 218,096 215,539 217,986 188,493